While Novo Nordisk may be glum about the upcoming patent expirations, the moment is one that generic-drug companies and peptide producers across India, China, and Europe have been rehearsing long and hard for, as they will be able to sell copycat versions of semaglutide
[76] [77] In a 72-week, phase IIIb open-label head-to-head trial of adults with obesity without diabetes, tirzepatide at the maximum tolerated dose produced greater mean weight loss than semaglutide and larger reductions in waist circumference, while gastrointestinal adverse events were the most common with both drugs
No matter your fitness concern, HealthKart has it all covered for you
Increases overall energy by enhancing the bodys ability to burn fat for fuel
Tuy nhin, thuc cn c tc dng gim cm gic thm n v thc y gim cn nhng ngi mc bnh tiu ng